The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 6, pp. 886-889. DOI 10.1345/aph.1C393
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finnegan, P. M
Right arrow Articles by Gleason, B. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finnegan, P. M
Right arrow Articles by Gleason, B. L

DRUG INFORMATION ROUNDS

Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension

Patrick M Finnegan

PharmD Student, St. Louis College of Pharmacy, St. Louis, MO

Brenda L Gleason, PharmD

Assistant Professor, Division of Pharmacy Practice, St. Louis College of Pharmacy

Reprints: Brenda L Gleason PharmD, Division of Pharmacy Practice, St. Louis College of Pharmacy, 4588 Parkview Pl., St. Louis, MO 63110-1088, FAX 314/454-3375, E-mail bgleason{at}stlcop.edu

OBJECTIVE: To review data concerning combined angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) therapy for hypertension.

DATA SOURCES: MEDLINE (1966–April 2003), IPA (1970–April 2003), and EMBASE (1974–April 2003) with search terms of ACE inhibitor, angiotensin receptor blocker, essential hypertension, and combination therapy.

DATA SYNTHESIS: ACE inhibitors provide incomplete blockade of the renin–angiotensin system, sometimes leading to loss of blood pressure control. Addition of ARBs may in theory further reduce blood pressure. Studies of combined ACE inhibitor and ARB therapy for managing hypertension were evaluated.

CONCLUSIONS: While studies have shown statistically significant blood pressure reductions with ACE/ARB combination therapy, clinical significance is lacking. Further trials are needed before routine use of the combination can be recommended.

Key Words: angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, hypertension




This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf
Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.